Nkarta IncNASDAQ:NKTX
- LAST PRICE4.7500
- TODAY'S CHANGE (%)0.1600 (3.4858%)
- Bid / Lots4.3800/ 1
- Ask / Lots5.2000/ 3
- Open / Previous Close4.6800 / 4.5900
- Day Range
- 52 Week Range
- Volume170,007
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NKTX |
|---|---|---|
| 09:32 ET | 2168 | 4.68 |
| 09:34 ET | 2308 | 4.67 |
| 09:41 ET | 800 | 4.64 |
| 09:45 ET | 1172 | 4.64 |
| 09:48 ET | 3179 | 4.64 |
| 09:50 ET | 100 | 4.64 |
| 09:52 ET | 200 | 4.63 |
| 09:54 ET | 1861 | 4.6 |
| 09:59 ET | 200 | 4.6 |
| 10:01 ET | 859 | 4.61 |
| 10:03 ET | 1100 | 4.6 |
| 10:06 ET | 200 | 4.6124 |
| 10:08 ET | 100 | 4.61 |
| 10:10 ET | 100 | 4.61 |
| 10:12 ET | 100 | 4.61 |
| 10:14 ET | 1184 | 4.62 |
| 10:17 ET | 100 | 4.62 |
| 10:19 ET | 100 | 4.62 |
| 10:21 ET | 100 | 4.63 |
| 10:24 ET | 100 | 4.62 |
| 10:26 ET | 100 | 4.62 |
| 10:28 ET | 1515 | 4.64 |
| 10:30 ET | 200 | 4.645 |
| 10:32 ET | 1165 | 4.63 |
| 10:37 ET | 100 | 4.64 |
| 10:48 ET | 100 | 4.625 |
| 10:50 ET | 120 | 4.6362 |
| 10:53 ET | 325 | 4.63 |
| 11:06 ET | 4901 | 4.64 |
| 11:09 ET | 300 | 4.63 |
| 11:11 ET | 1000 | 4.63 |
| 11:15 ET | 1625 | 4.62 |
| 11:20 ET | 1100 | 4.61 |
| 11:26 ET | 500 | 4.6 |
| 11:36 ET | 505 | 4.6 |
| 11:38 ET | 853 | 4.61 |
| 11:40 ET | 200 | 4.605 |
| 11:42 ET | 300 | 4.61 |
| 11:51 ET | 1364 | 4.605 |
| 11:54 ET | 100 | 4.605 |
| 12:03 ET | 100 | 4.62 |
| 12:09 ET | 100 | 4.63 |
| 12:18 ET | 500 | 4.63 |
| 12:20 ET | 292 | 4.64 |
| 12:21 ET | 1543 | 4.665 |
| 12:27 ET | 100 | 4.665 |
| 12:30 ET | 100 | 4.68 |
| 12:32 ET | 100 | 4.665 |
| 12:36 ET | 700 | 4.68 |
| 12:38 ET | 100 | 4.71 |
| 12:43 ET | 100 | 4.72 |
| 12:45 ET | 800 | 4.75 |
| 12:48 ET | 100 | 4.75 |
| 12:50 ET | 100 | 4.75 |
| 12:52 ET | 100 | 4.75 |
| 12:54 ET | 100 | 4.75 |
| 12:56 ET | 200 | 4.75 |
| 12:57 ET | 247 | 4.7475 |
| 12:59 ET | 1570 | 4.755 |
| 01:01 ET | 1000 | 4.77 |
| 01:14 ET | 100 | 4.77 |
| 01:24 ET | 11463 | 4.79 |
| 01:26 ET | 2200 | 4.8 |
| 01:28 ET | 100 | 4.8 |
| 01:32 ET | 1602 | 4.81 |
| 01:35 ET | 100 | 4.81 |
| 01:42 ET | 100 | 4.82 |
| 01:44 ET | 1200 | 4.83 |
| 01:46 ET | 793 | 4.84 |
| 01:48 ET | 1100 | 4.83 |
| 01:50 ET | 200 | 4.83 |
| 01:51 ET | 200 | 4.83 |
| 01:53 ET | 300 | 4.83 |
| 01:55 ET | 200 | 4.83 |
| 01:57 ET | 400 | 4.83 |
| 02:00 ET | 2117 | 4.8 |
| 02:02 ET | 2067 | 4.77 |
| 02:04 ET | 400 | 4.7575 |
| 02:06 ET | 400 | 4.75 |
| 02:09 ET | 445 | 4.765 |
| 02:13 ET | 100 | 4.76 |
| 02:15 ET | 1600 | 4.75 |
| 02:20 ET | 341 | 4.75 |
| 02:22 ET | 500 | 4.75 |
| 02:24 ET | 600 | 4.75 |
| 02:26 ET | 500 | 4.74 |
| 02:27 ET | 200 | 4.735 |
| 02:29 ET | 200 | 4.735 |
| 02:31 ET | 800 | 4.745 |
| 02:33 ET | 2143 | 4.7325 |
| 02:36 ET | 100 | 4.735 |
| 02:42 ET | 100 | 4.74 |
| 02:44 ET | 200 | 4.735 |
| 02:45 ET | 300 | 4.735 |
| 02:47 ET | 915 | 4.74 |
| 02:49 ET | 773 | 4.73 |
| 02:54 ET | 200 | 4.73 |
| 02:58 ET | 445 | 4.73 |
| 03:00 ET | 100 | 4.73 |
| 03:02 ET | 100 | 4.73 |
| 03:03 ET | 100 | 4.73 |
| 03:05 ET | 505 | 4.73 |
| 03:12 ET | 100 | 4.73 |
| 03:14 ET | 100 | 4.73 |
| 03:16 ET | 200 | 4.73 |
| 03:18 ET | 1400 | 4.72 |
| 03:20 ET | 700 | 4.7206 |
| 03:21 ET | 1413 | 4.685 |
| 03:23 ET | 100 | 4.685 |
| 03:25 ET | 1100 | 4.69 |
| 03:27 ET | 200 | 4.69 |
| 03:30 ET | 200 | 4.69 |
| 03:32 ET | 1787 | 4.68 |
| 03:34 ET | 1500 | 4.69 |
| 03:36 ET | 900 | 4.7 |
| 03:38 ET | 2800 | 4.73 |
| 03:39 ET | 200 | 4.73 |
| 03:43 ET | 202 | 4.74 |
| 03:45 ET | 254 | 4.73 |
| 03:48 ET | 300 | 4.73 |
| 03:50 ET | 3691 | 4.73 |
| 03:52 ET | 200 | 4.74 |
| 03:54 ET | 1333 | 4.75 |
| 03:56 ET | 4107 | 4.75 |
| 03:57 ET | 3385 | 4.7693 |
| 03:59 ET | 23758 | 4.75 |
May 12, 2023
--Stifel Trims Price Target on Nkarta to $18 From $21, Maintains Buy Rating, from 9:51AM ET on Friday May 12, 2023 by MT Newswires
9:51AM ET on Friday May 12, 2023 by MT Newswires
May 11, 2023
BRIEF-Nkarta Reports First Quarter 2023 Financial Results , from 5:03PM ET on Thursday May 11, 2023 by Thomson Reuters
5:03PM ET on Thursday May 11, 2023 by Thomson ReutersNkarta Reports First Quarter 2023 Financial Results and Corporate Highlights, from 4:02PM ET on Thursday May 11, 2023 by GlobeNewswire
4:02PM ET on Thursday May 11, 2023 by GlobeNewswireNkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma, from 4:01PM ET on Thursday May 11, 2023 by GlobeNewswire
4:01PM ET on Thursday May 11, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nkarta Inc | 232.4M | -1.9x | --- |
Olema Pharmaceuticals Inc | 231.1M | -2.1x | --- |
Cytodyn Inc | 237.3M | -1.1x | --- |
Quantum-Si Inc | 239.1M | -2.0x | --- |
Oric Pharmaceuticals Inc | 239.9M | -2.4x | --- |
Celcuity Inc | 242.9M | -4.2x | --- |
Company Information
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. The Company’s product candidates include NKX101 and NKX019, which are in ongoing Phase I clinical trials. NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors. It is engineered with a chimeric antigen receptor (CAR) targeting NKG2D ligands on tumor cells. NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed CAR for enhanced tumor cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support.
Contact Information
- Headquarters
- 6000 Shoreline Court, Suite 102SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 415-582-4923
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Ali Behbahani
- President, Chief Executive Officer, Director
- Paul Hastings
- Chief Financial Officer, Chief Business Officer
- Nadir Mahmood
- Chief Technical Officer
- Ralph Brandenberger
- Chief Scientific Officer
- James Trager
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $232.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.49 |
Book Value | $7.62 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
